Today the headline is Eli Lilly, a household name in medicine, making a $3.8 billion bet on psychedelic-based treatments. To understand why this matters, think about who Eli Lilly is: they are one of the largest and most trusted drug makers on the planet. When a company that size commits billions, it is not gambling on a fad. It is saying they see a real product, a real market, and a real path to approval. This is the kind of move that pulls other giants in behind it. Meanwhile, the smaller companies in this space had a decent day — MindMed rose 4.6 percent, and Compass Pathways and Numinus ticked up too. That rise is the market quietly nodding along: the big money arriving makes the whole field feel safer.
Beneath the news, a clear thread is forming. For years, psychedelic medicine lived on the edges — small trials, brave patients, tiny companies scraping for funding. Today's deal marks a handoff. The pioneers proved these treatments might work; now the industrial giants are stepping in to make them real, tested, and available at scale. At the same time, two other currents are running fast. Ibogaine — a plant-based treatment showing striking promise for veterans with trauma — is being fast-tracked by regulators, which means the government agreed to speed up its review. That speed is exciting, but it will almost certainly draw hard questions about heart safety, because ibogaine can strain the heart, and honest science has to answer that before anyone celebrates. The highest path here is not the fastest one — it is the one where big money brings rigor, and speed brings honesty with it.
For the real people inside this story, today changes the feeling in the room. A veteran who has tried every approved pill and still wakes at 3 a.m. reliving the worst day of his life now hears that a company with real weight is building treatments meant for people like him. A mother watching her daughter sink into a depression that nothing has touched sees that this is no longer a fringe hope — it is being backed by the same kind of company that makes the medicine already in her cabinet. That shift matters. It means the wait might finally be measured in a few years instead of forever, and it means the people building these treatments now have the resources to do it carefully, so that safe help actually reaches the kitchen tables where it is needed.
What is being called in cannot be called back. The currents forming in legislation, in research, in culture — OOTW reads them daily, so you don't have to navigate them alone.
What is being called in cannot be called back.
70%
Major news outlet will question ibogaine's heart risks or political push
Ibogaine, a powerful psychedelic being fast-tracked by US drug regulators for veteran treatment, has a known risk of causing dangerous heart rhythm problems. A major newspaper or magazine is likely to publish a deep investigation asking whether the political push to approve it is moving too fast and putting people at risk. This matters because fast-tracking a drug with cardiac risks — especially under political pressure — could affect patient safety and public trust.
→ A major media investigation into ibogaine's heart risks or political motivations is more likely than not before September 2026.
Resolves: 2026-09-15 · Global
CULTURAL
the precise call ▾
The ibogaine fast-track will draw a critical investigative piece questioning cardiac safety or political motives (MAHA angle) in a major outlet before 2026-09-15.. Fast-track + Trump/MAHA framing + a psychoactive drug with known cardiac risk is an irresistible editorial target. Near-term and cleanly verifiable against named outlets. || RESOLUTION RULE: YES if, by 2026-09-15, a major outlet (NYT, WaPo, WSJ, STAT News, Reuters, Bloomberg, The Atlantic, or equiva
68%
Veteran groups will formally demand ibogaine access from VA or Congress
Veterans' advocacy organizations are expected to use the FDA (the US drug regulator) fast-track designation for ibogaine as a rallying moment to publicly demand access through the VA (the US Department of Veterans Affairs) or through new laws. A petition or open letter is a cheap, fast way for these groups to get attention and pressure lawmakers. This matters because organized veteran pressure has historically moved drug policy faster than almost anything else.
→ Within weeks of the FDA fast-track announcement, expect a named veteran organization to formally and publicly demand ibogaine access.
Resolves: 2026-09-19 · USA
POLICY
the precise call ▾
A veteran-organized coalition will publicly petition the VA or Congress for ibogaine access citing the fast-track within 8 weeks.. The fast-track headline is exactly the opening advocates mobilize around; a petition or public letter is the lowest-cost, highest-visibility action for veteran groups (e.g., VETS, Heroic Hearts). Near-term and falsifiable. || RESOLUTION RULE: YES if, by 2026-09-19, a named veteran-focused organizati
60%
A US state will fund or propose an ibogaine program for veterans
Texas has already put state money into ibogaine research for veterans, and the new federal fast-track gives other states political cover to follow. States like Texas, Kentucky, or Arizona — where veteran communities are large and politically powerful — may announce new funding, a pilot program, or a bill to explore ibogaine or other psychedelics as veteran treatments. This matters because state-level action can happen much faster than federal approval and creates real access for real people.
→ At least one US state is likely to announce new ibogaine or veteran psychedelic funding or legislation before November 2026.
Resolves: 2026-11-01 · USA
POLICY
the precise call ▾
At least one state (likely TX, KY, or AZ) will announce new ibogaine or veteran-psychedelic funding/pilot legislation before 2026-11-01.. Texas already funded ibogaine research; the federal fast-track gives red-state legislators political cover to expand. Veteran framing is bipartisan. Specific candidate states named. || RESOLUTION RULE: YES if, by 2026-11-01, at least one U.S. state announces new ibogaine or veteran-psychedelic fundi
63%
Regulators or scientists will formally flag ibogaine's dangerous heart side effects
Ibogaine is known to cause a serious heart condition called QT prolongation, which can trigger a life-threatening irregular heartbeat. As the drug moves through the fast-track approval process, regulators, drug safety experts, or scientists are expected to formally raise this concern — either by publishing new safety data, issuing a warning, or putting conditions on how trials must be run. This matters because formal safety flags can slow or reshape a drug's path to approval.
→ Before late October 2026, expect an official or peer-reviewed safety response specifically addressing ibogaine's risk of causing dangerous heart rhythms.
Resolves: 2026-10-25 · USA
REGULATORY
the precise call ▾
The ibogaine fast-track triggers a formal cardiac-safety counterweight (FDA gating, peer-reviewed hERG/QT caution, or new mechanistic data) before 2026-10-15.. Consensus of 4 agents (fda_reviewer, neuroscientist, journalist, dea_officer). Ibogaine's QT-prolongation/torsades risk is the single most documented safety concern; a fast-track designation predictably forces a formal cardiac gating response. Anchored to a specific, dated catalyst. || RESOLUTION RU
55%
Lab study will show depression changes how brain cells respond to antidepressants over time
Scientists are using a technique that turns human skin or blood cells into working brain cells in a dish — called iPSC (induced pluripotent stem cell)-derived neurons — to study why some people's depression doesn't respond to normal treatments. A study comparing brain cells from people with treatment-resistant depression (TRD) to cells from healthy people is expected to show that the two groups respond differently to fast-acting antidepressants as time passes. This matters because it could explain why some people don't get better and point toward more personalized treatments.
→ A lab study using human-derived brain cells may soon show, in a published paper, exactly how treatment-resistant depression alters how brain cells respond to antidepressants.
Resolves: 2026-09-30 · Global
RESEARCH
the precise call ▾
The iPSC-derived neuron rapid-antidepressant study will report time-dependent plasticity differences between TRD and healthy donors in a peer-reviewed journal before 2026-09-30.. The underlying signal names the exact comparison (TRD vs healthy iPSC donors, time-dependent plasticity). Publishable mechanistic data differentiating rapid-acting antidepressant response. Falsifiable against the published-record. || RESOLUTION RULE: YES if, by 2026-09-30, a peer-reviewed paper (or